ZimVie Shareholders Receive Final Payout as ARCHIMED Acquisition Concludes

The publicly traded chapter of ZimVie Inc. has officially closed. The dental technology company completed its acquisition by healthcare-focused private equity firm ARCHIMED in a transaction valued at $730 million. ZimVie shares ceased trading on the NASDAQ exchange in October, with shareholders receiving a final cash distribution of $19 per share—a figure that nearly doubled the stock’s 90-day average price prior to the deal’s announcement.

Shareholders Approve Premium Buyout

In a special meeting held on October 10, ZimVie stockholders overwhelmingly voted to approve the acquisition. Trading was halted after the market closed on October 17, with NASDAQ formally suspending the listing on October 21. The transaction concluded on October 20, converting every outstanding share into a $19 cash payment.

This payout represented a substantial 99% premium over the company’s 90-day average share price of $9.57, which stood when the acquisition was first revealed in July. The buyout concludes ZimVie’s brief tenure as an independent entity following its spin-off from Zimmer Biomet in 2022.

Leadership Transition and Strategic Focus

With the acquisition finalized, ZimVie’s entire executive leadership team has been replaced. Former CEO Vafa Jamali and CFO Richard Heppenstall have both stepped down. Control of the now privately-held company has transitioned to André-Michel Ballester and Bryan Alterman, a standard procedural change following acquisitions of this magnitude.

Should investors sell immediately? Or is it worth buying ZimVie?

This ownership transition follows ZimVie’s earlier strategic move to divest its spine business to H.I.G. Capital for $375 million, allowing the company to concentrate exclusively on its dental operations. Under ARCHIMED’s ownership, this focused approach on the dental sector is expected to intensify.

Investment Chapter Closed

For market participants, the acquisition eliminates any future opportunity to invest in ZimVie through public markets. Shareholders have received their final distributions, definitively concluding the company’s period as a publicly traded entity. Going forward, insights into business performance will remain confidential with ARCHIMED, as the company will no longer be subject to public market reporting requirements or regulatory oversight.

While ZimVie continues its internal operations, including a current transition to Oracle Cloud systems, the public market has rendered its final verdict on the dental specialist. The curtain has fallen on this particular investment opportunity.